Skip to Content
Merck
CN
All Photos(1)

Documents

MAB3121

Sigma-Aldrich

Anti-Bcl-XL and BclXs Antibody, clone 7B2.5

clone 7B2.5, Chemicon®, from mouse

Synonym(s):

Anti-BCL-XL

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

7B2.5, monoclonal

species reactivity

human

manufacturer/tradename

Chemicon®

technique(s)

flow cytometry: suitable
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable

isotype

IgG3

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

human ... BCL2L1(598)

Related Categories

Specificity

Apoptosis, or programmed cell death, is a well-documented phenomenon in many cellular systems (Cohen, 1991). It plays a key role in tissue and organ development, as well as in adult tissues during cell turnover. Apoptosis can be induced by a variety of internal and external stimuli including growth factor deprivation, cytokine treatment, antigen-receptor engagement, cell-cell interactions, irradiation and glucocorticoid treatment (Cohen & Duke, 1992). Bcl-2 and one of its homologues, Bcl-XL, protect cells from apoptosis (Nunez & Clarke, 1994; Cory, 1995), while other homologues of Bcl-2 such as Bax, Bad and Bak have been shown to enhance apoptosis (Oltvai, 1993; Farrow, 1995; Chittenden, 1995; Kiefer, 1995). Bcl-XL has been shown to block apoptosis which is induced by a variety of stimuli and, under certain conditions, offers greater protection against apoptosis than Bcl-2 (Boise, 1993; Gottschalk, 1994; Gonzalez-Garcia, 1995; Dole, 1995; Shimizu, 1995). In contrast, Bad and Bax inhibit the protective functions of Bcl-XL and Bcl-2, respectively. Although heterodimerization between Bcl-XL, Bad and Bcl-2/Bax was originally thought to be essential for the differential anti-apoptotic activity of Bcl-XL and Bcl-2 (Oltvai, 1993; Yin, 1994); other results suggest that the formation of heterodimers may not be necessary for this death-repressing activity Cheng, 1996; Gottschalk, 1996). This antibody recognizes Human Bcl-XL (Mr 29 kDa) and Bcl-Xs (Mr 21 kDa).

Immunogen

Recombinant Bcl-XS.

Application

Detect Bcl-XL & BclXs using this Anti-Bcl-XL & BclXs Antibody, clone 7B2.5 validated for use in FC, IP, WB, IH.
Flow cytometry:
Immunoprecipitation (Cheng, 1996; Gottschalk, 1996)

Immunohistochemistry (Foreman, 1996; Wrone-Smith, 1995)

Western blotting: ( 0.5 μg/mL)

Optimal working dilutions must be determined by end user.
Research Category
Apoptosis & Cancer
Research Sub Category
BCL2 & Inhibition

Physical form

Format: Purified
Purified immunoglobulin - Ig fraction. Liquid in borate buffer saline, pH 8.2.

Storage and Stability

Store at 2-8°C for up to 12 months.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Pictograms

Health hazard

Signal Word

Danger

Hazard Statements

Hazard Classifications

Repr. 1B

WGK

nwg

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Elisa Sala et al.
Molecular cancer research : MCR, 6(5), 751-759 (2008-05-07)
BRAF-activating mutations have been reported in several types of cancer, including melanoma ( approximately 70% of cases), thyroid (30-70%), ovarian (15-30%), and colorectal cancer (5-20%). Mutant BRAF has constitutive kinase activity and causes hyperactivation of the mitogen-activated protein kinase pathway.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service